Department of Biochemistry, Christian Medical College, Bagayam, Vellore, 632002, Tamil Nadu, India.
J Med Toxicol. 2011 Jun;7(2):118-24. doi: 10.1007/s13181-010-0103-9.
Cyclophosphamide (CP) is widely used in the treatment of cancer and non-malignant disease states such as rheumatoid arthritis. Hemorrhagic cystitis is a major dose-limiting side effect of CP. The incidence of this side effect is related to the dosage and can be as high as 75%. Elimination of the side effects of CP can lead to better tolerance of the drug, and a more efficient therapy can be achieved for patients in need of CP treatment. Several studies have demonstrated that oxidative stress and neutrophil infiltration play important roles in CP-induced bladder damage. Glutamine is utilized under clinical conditions for preventing chemotherapeutic drug-induced side effects, based on its ability to attenuate oxidative stress. The aim of the study is to verify whether glutamine prevents CP-induced oxidative stress and bladder damage using a rat model. Adult male rats were administered 150 mg/kg body weight of CP intraperitoneally. Glutamine pretreated rats were administered 1 g/kg body weight of glutamine orally 2 h before the administration of CP. Vehicle/glutamine-treated rats served as controls. All the rats were killed 16 h after the dose of CP/vehicle. The urinary bladders were removed and used for light microscopic and biochemical studies. The markers of oxidative stress including malondialdehyde content, protein carbonyl content, protein thiol, and myeloperoxidase activity, a marker of neutrophil infiltration, were measured in bladder homogenates. CP treatment induced hemorrhagic cystitis in the rats. Pretreatment with glutamine significantly reduced CP-induced lipid peroxidation (p < 0.01), protein oxidation (p < 0.01), and increase in myeloperoxidase activity (p < 0.05). However, it did not prevent CP-induced bladder damage. The results of the present study show that glutamine pretreatment does not attenuate CP-induced hemorrhagic cystitis, although it prevents CP-induced oxidative stress and neutrophil infiltration significantly. It is therefore necessary to clarify the utility of glutamine as a chemoprotective agent before it is recommended in the market as a nutrient supplement.
环磷酰胺(CP)广泛用于治疗癌症和非恶性疾病状态,如类风湿性关节炎。出血性膀胱炎是 CP 的主要剂量限制副作用。这种副作用的发生率与剂量有关,高达 75%。消除 CP 的副作用可以导致更好地耐受药物,并且可以为需要 CP 治疗的患者实现更有效的治疗。几项研究表明,氧化应激和中性粒细胞浸润在 CP 诱导的膀胱损伤中起重要作用。在临床情况下,谷氨酰胺被用于预防化疗药物引起的副作用,基于其减轻氧化应激的能力。本研究旨在使用大鼠模型验证谷氨酰胺是否可预防 CP 诱导的氧化应激和膀胱损伤。成年雄性大鼠腹膜内给予 150mg/kg 体重的 CP。CP 给药前 2 小时,谷氨酰胺预处理大鼠给予 1g/kg 体重的谷氨酰胺口服。载体/谷氨酰胺处理的大鼠作为对照。CP/载体给药后 16 小时处死所有大鼠。取出膀胱并用于光镜和生化研究。在膀胱匀浆中测量氧化应激标志物,包括丙二醛含量、蛋白质羰基含量、蛋白质巯基和髓过氧化物酶活性,这是中性粒细胞浸润的标志物。CP 治疗诱导大鼠出血性膀胱炎。谷氨酰胺预处理显着降低 CP 诱导的脂质过氧化(p<0.01)、蛋白质氧化(p<0.01)和髓过氧化物酶活性增加(p<0.05)。然而,它不能预防 CP 诱导的膀胱损伤。本研究结果表明,尽管谷氨酰胺预处理显着预防 CP 诱导的氧化应激和中性粒细胞浸润,但不能减轻 CP 诱导的出血性膀胱炎。因此,在推荐谷氨酰胺作为营养补充剂在市场上使用之前,有必要阐明其作为化学保护剂的实用性。